Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance
Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance
复制标题
DOI：
10.21873/invivo.11645
复制
发表时间：
2019-09-01
期刊：
影响因子：
2.3
通讯作者：
Kim, Choung-Soo
中科院分区：
文献类型：
--
作者：
Choi, Se Young;Lim, Bumjin;Kim, Choung-Soo
目的：通过比较健康志愿者和局限性前列腺癌患者（包括处于主动监测下的患者），评估循环肿瘤细胞（CTC）检测的临床疗效。材料和方法：对45例前列腺癌患者和17例健康志愿者外周血CTC计数进行比较。基于上皮细胞粘附分子（EpCAM）的表达鉴定CTC，并使用SMART BIOPSYTM系统计数。结果：肿瘤患者EpCAM+细胞数量明显高于健康志愿者。在低风险患者（n=9）中，2例分期升高，6例分级升高。在那些分期较高的患者中，有1例EpCAM（+）。在这些升级的病例中，3例为EpCAM（+）。在T2期肿瘤中，Gleason模式5的存在与EpCAM阳性呈正相关（rho=0.59，p
Aim: To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance. Materials and Methods: CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY (TM) SYSTEM. Results: The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM(+). Among those cases up-graded, three were EpCAM(+). In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p